Main description:

Given the amount and complexity of information surrounding the the target specific oral anticoagulants a lengthy didactic educational format has the potential to be overwhelming to the reader and difficult to translate and apply to direct patient care. The proposed book will educate clinicians utilizing a series of clinical cases to simultaneously develop the readers' knowledge base, problem-solving skills, and practically apply their new knowledge to a variety of clinical situations. These will be short focused case presentations that provide critical information and pose questions to the reader at key points in the decision making process. The cases will be relevant to what clinicians will encounter not only on a daily basis, but also reflective of scenarios that clinicians will not encounter regularly, but that they will have to act upon (e.g. a bleeding patient, patient scheduled for elective or emergent procedure, patient with changing renal function, patient on drugs that have a plausible yet unstudied drug interaction with a target specific oral anticoagulant etc). Included in the case studies will be evidence-based discussions (with appropriate references) that provide immediate feedback on the different treatment alternatives that were offered. The case studies will be designed to instruct the reader how to select and effectively utilize the most appropriate agent for a given clinical scenario. They will focus on key features of the target specific oral anticoagulants, what they have in common, how they are unique from each other, as well as illustrating the clinical decision process one should take when selecting an agent or managing a patient already receiving one of the target specific oral agents.

Contents:

Table of Contents Part I Introduction
1

Part II Atrial Fibrillation
2: CHA2DS2VASc and HAS-BLED risk stratification tools
3: Male with priority of ischemic stroke reduction
4: Choosing an anticoagulant in an elderly patient
5: Patient with prior history of gastrointestinal hemorrhage
6: Patients with a history of intracranial hemorrhage
7: Concerns with anticoagulant adherence
8: Oral Anticoagulants in stable moderate Chronic Kidney Disease
9: Oral Anticoagulants in severe renal dysfunction
10: Oral Anticoagulants in patients with variable renal function
11: Patient with concomitant stable Coronary Artery Disease
12: Patient with concomitant acute venous thromboembolism
13: Patient with concomitant Mitral Valve Stenosis
14: Patient with concomitant Aortic Valve Stenosis

Part III Warfarin management
15: Best practices for switching from stable warfarin
16: Patient-centered strategies for improving warfarin management

Part IV Venous Thromboembolism (VTE)
17: Provoked versus unprovoked VTE
18: VTE prophylaxis in hip and knee replacement surgery
19: VTE prophylaxis in the intensive care unit
20: VTE and recent drug eluting stent placement
21: Acute VTE in a patient with moderate chronic kidney disease
22: Oral anticoagulation and duration in recurrent VTE
23: Pulmonary embolism (PE) with thrombolytic therapy

Part V Acute Coronary Syndrome (ACS)
24: Patient on oral anticoagulant presenting with ACS
25: Oral anticoagulant therapy post-percutaneous coronary intervention
26: ST-segment elevation myocardial infarction (lytic candidate) on oral anticoagulant
27: ACS with bypass surgery

Part VI Drug Interactions
28: Anticoagulant drug-drug interactions with CYP 3A4 inhibitors
29: Significance of P-glycoprotein (P-gp) drug-drug interactions
30: Considerations with pharmacodynamics drug-drug interactions
31: Management of direct oral anticoagulants with mixed P-gp/3A4 drug-drug interactions
32: Pharmacokinetic drug-drug interactions with warfarin

Part VII Special Populations
33: Chronic Pain Management with anticoagulation
34: Anticoagulation management in atrial fibrillation catheter ablation
35: Anticoagulation management considerations for mechanical valves
36: Management of antiphospholipid antibody syndrome (APS)
37: VTE and Pregnancy
38: VTE in active Malignancy
39: Anticoagulation management in patients undergoing gastric bypass procedures
40: Patient presenting with minor bleeding
41: Patient presenting with major, life-threatening bleeding
42: Overdose of dabigatran